| Share-Based Payment Arrangement, Option, Activity [Table Text Block] |
| | | Shares Available | | | Number of Options | | | Weighted Average | |
| | | For Grant | | | Outstanding | | | Exercise Price | |
| Balance at December 31, 2025 | | | 10,443,566 | | | | 7,556,434 | | | $ | 0.44 | |
| Granted | | | (216,448 | ) | | | 216,448 | | | $ | 1.13 | |
| Exercised | | | 183,510 | | | | (183,510 | ) | | $ | 0.23 | |
| Cancelled | | | 18,726 | | | | (18,726 | ) | | $ | 2.11 | |
| Balance at March 31, 2026 | | | 10,429,354 | | | | 7,570,646 | | | $ | 0.66 | |
|
| | | Shares Available For Grant | | | Number of Options Outstanding | | | Weighted Average Exercise Price | |
| Balance at December 31, 2024 | | | 1,183,618 | | | | 7,210,742 | | | $ | 0.49 | |
| Approved pool increase | | | 9,605,640 | | | | - | | | | - | |
| Granted | | | (837,036 | ) | | | 837,036 | | | | 2.14 | |
| Forfeited | | | 107,323 | | | | (107,323 | ) | | | 0.23 | |
| Cancelled | | | 384,021 | | | | (384,021 | ) | | | 0.83 | |
| Balance at December 31, 2025 | | | 10,443,566 | | | | 7,556,434 | | | $ | 0.44 | |
|
| Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] |
| Stock Price | | $1.08 | - | $1.69 | |
| Expected dividend yield | | | 0% | | |
| Expected stock price volatility | | 162% | - | 164% | |
| Risk-free interest rate | | 3.73% | - | 3.86% | |
| Expected term (years) | | | 6.08 | | |
|
| Stock Price | $ 1.42 | |
| Expected dividend yield | -% | |
| Expected stock price volatility | 189% | |
| Risk-free interest rate | 4.69% | |
| Expected term (years) | 6.08 | |
| Stock Price | $ 8.70 | |
| Expected dividend yield | -% | |
| Expected stock price volatility | 146% | |
| Risk-free interest rate | 3.77% | |
| Expected term (years) | 6.08 | |
|
| Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] |
| | | Three Months Ended March 31, | |
| | | 2026 | | | 2025 | |
| Cost of revenue | | $ | 18 | | | $ | 1 | |
| Research and development | | | - | | | | 3 | |
| Selling, general and administrative | | | 147 | | | | 137 | |
| Total stock-based compensation | | $ | 165 | | | $ | 141 | |
|
| | | Year Ended December 31, | |
| | | 2025 | | | 2024 | |
| Cost of revenue | | $ | 58 | | | $ | 12 | |
| Research and development | | | 61 | | | | 13 | |
| Selling, general and administrative | | | 635 | | | | 861 | |
| Total stock-based compensation | | $ | 754 | | | $ | 886 | |
|